Tanja Obradovic: BioXcel Therapeutics received Fast Track designation by the FDA for BXCL701

Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON, shared on LinkedIn:

“Biotech companies are turning tide when it comes to financing and especially companies that acquire supportive early clinical data while investors are still mostly on the side when it comes to those with preclinical package. One of the biotechs at the forefront of AI-guided development, BioXcel Therapeutics, showcases successful navigation of the financing while reaching late-stage clinical development.

Today it received Fast Track designation by the FDA for BXCL701, oral innate immune activator designed to initiate inflammation in the tumor microenvironment for combination with a checkpoint inhibitor for the treatment of patients with metastatic small cell neuroendocrine prostate cancer (SCNC) with progression on chemotherapy and no evidence of microsatellite instability. It has shown positive clinical proof of concept in both SCNC and adenocarcinoma with positive survival results from Phase 2 trial.”

View additional information.
Source: Tanja Obradovic/LinkedIn